Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Schaper Benz & Wise Investment Counsel Inc. WI

Schaper Benz & Wise Investment Counsel Inc. WI raised its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,302 shares of the biotechnology company’s stock after purchasing an additional 164 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Axon Enterprise were worth $10,283,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after acquiring an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after acquiring an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after acquiring an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after acquiring an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment acquired a new stake in shares of Axon Enterprise during the third quarter valued at $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $639.69, for a total transaction of $639,690.00. Following the sale, the director now directly owns 24,259 shares in the company, valued at approximately $15,518,239.71. This trade represents a 3.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Joshua Isner sold 1,291 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $642.43, for a total value of $829,377.13. Following the sale, the president now owns 181,892 shares in the company, valued at approximately $116,852,877.56. The trade was a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,146 shares of company stock worth $3,262,847. 6.10% of the stock is currently owned by company insiders.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $526.40 on Friday. The company has a market cap of $40.33 billion, a P/E ratio of 136.02, a PEG ratio of 5.17 and a beta of 1.12. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $715.99. The business’s 50-day simple moving average is $599.42 and its 200 day simple moving average is $529.53.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of analyst reports. JMP Securities reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “hold” rating and set a $625.00 target price on the stock. in a research report on Thursday, February 20th. Needham & Company LLC reiterated a “buy” rating and set a $600.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 26th. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Finally, Barclays set a $726.00 target price on Axon Enterprise and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $587.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.